SG11202107720UA - Cnx/erp57 inhibitor for use in the treatment or prevention of cancer - Google Patents

Cnx/erp57 inhibitor for use in the treatment or prevention of cancer

Info

Publication number
SG11202107720UA
SG11202107720UA SG11202107720UA SG11202107720UA SG11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA
Authority
SG
Singapore
Prior art keywords
cnx
cancer
prevention
treatment
erp57
Prior art date
Application number
SG11202107720UA
Inventor
Frederic Bard
Anh Tuan Nguyen
Ros Manon
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11202107720UA publication Critical patent/SG11202107720UA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4727Calcium binding proteins, e.g. calmodulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/99Isomerases (5.)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11202107720UA 2019-01-31 2020-01-30 Cnx/erp57 inhibitor for use in the treatment or prevention of cancer SG11202107720UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201900943X 2019-01-31
PCT/SG2020/050044 WO2020159445A1 (en) 2019-01-31 2020-01-30 Cnx/erp57 inhibitor for use in the treatment or prevention of cancer

Publications (1)

Publication Number Publication Date
SG11202107720UA true SG11202107720UA (en) 2021-08-30

Family

ID=71842463

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107720UA SG11202107720UA (en) 2019-01-31 2020-01-30 Cnx/erp57 inhibitor for use in the treatment or prevention of cancer

Country Status (4)

Country Link
EP (1) EP3917571A4 (en)
CN (1) CN113365661A (en)
SG (1) SG11202107720UA (en)
WO (1) WO2020159445A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106188B (en) * 2021-12-30 2022-07-19 深圳市人民医院 Nano antibody targeting disulfide isomerase A3 and application thereof
WO2024008960A1 (en) 2022-07-08 2024-01-11 Agency For Science, Technology And Research Cnx antigen-binding molecules

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
SU1441787A1 (en) 1987-04-29 1990-09-23 Институт Белка Ан Ссср Method of producing peptides and proteins in cell-less translation system
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
SU1705302A1 (en) 1988-12-22 1992-01-15 Институт Белка Ан Ссср Method of preparative genes expression in the cell-free system of coupled transcription/translation
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
CA2064754C (en) 1989-07-31 1996-06-18 Vladimir Ivanovich Baranov Method of preparing polypeptides in a cell-free translation system
KR0185192B1 (en) 1989-10-05 1999-04-01 제임스 더블유. 데이비 Cell-free synthesis and isolation of novel genes and polypeptides
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
ES2155822T3 (en) 1990-12-06 2001-06-01 Affymetrix Inc COMPOUNDS AND ITS USE IN A BINARY SYNTHESIS STRATEGY.
JPH06508022A (en) 1991-02-21 1994-09-14 ギリアド サイエンシズ,インコーポレイテッド Biomolecule-specific aptamers and production methods
JP2001524926A (en) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ Method for synthesizing a heterogeneous library of oligomers
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
USRE45795E1 (en) 1994-08-20 2015-11-10 Gendaq, Ltd. Binding proteins for recognition of DNA
ES2176484T3 (en) 1995-08-18 2002-12-01 Morphosys Ag PROTEIN BANKS / (POLI) PEPTIDES.
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6083682A (en) 1997-12-19 2000-07-04 Glaxo Group Limited System and method for solid-phase parallel synthesis of a combinatorial collection of compounds
AU751487B2 (en) 1998-03-17 2002-08-15 Gendaq Limited Nucleic acid binding proteins
EP1230355A2 (en) 1999-10-01 2002-08-14 Sangamo Biosciences Inc. Dna library and its use in methods of selecting and designing polypeptides
EP2320235A1 (en) * 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker for prostate cancer diagnosis
WO2013011153A2 (en) * 2011-07-21 2013-01-24 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the prognosis and treatment of metastasis in breast cancer
CN108277275B (en) * 2017-01-03 2021-11-09 中山大学附属口腔医院 Use of calnexin in screening of drugs for diagnosis or treatment of tumor-related diseases
US11740242B2 (en) * 2017-07-14 2023-08-29 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
EP3692371A4 (en) * 2017-10-04 2021-06-09 Agency for Science, Technology and Research Biomarkers to detect and characterise cancer
CN108309988B (en) * 2018-05-04 2020-05-26 遵义医学院 ERp57 inhibitor compound and application

Also Published As

Publication number Publication date
CN113365661A (en) 2021-09-07
EP3917571A1 (en) 2021-12-08
WO2020159445A1 (en) 2020-08-06
EP3917571A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
PL3672639T3 (en) Combination product of a bcl-2 inhibitor and ibrutinib for use in the prevention and/or treatment of cancer
IL272948B1 (en) Enpp1 inhibitors and their use for the treatment of cancer
IL255189B2 (en) A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
IL279347A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
HK1259545A1 (en) Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
IL290011A (en) Ezh2 inhibition in combination therapies for the treatment of cancers
EP4081527A4 (en) The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
IL281999A (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
IL290415A (en) Deuterated compounds for use in the treatment of cancer
EP3888648A4 (en) Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
SG11202107720UA (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
IL288522A (en) Egfr inhibitor for the treatment of cancer
IL276668A (en) Thioredoxin reductase inhibitors for use in the treatment of cancer
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
IL276905A (en) Treatment and prevention of pre-eclampsia
ZA202202617B (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
IL290656A (en) Lurbinectedin in the treatment of malignant mesothelioma
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL284124A (en) Quinoline derivatives for use in the treatment or prevention of cancer
IL270306A (en) Prevention and treatment of pre-myeloid and myeloid malignancies
IL268860A (en) Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling
EP3987032A4 (en) Methods and compositions for the treatment of cancer
HUP1900281A1 (en) Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer
GB201815694D0 (en) Prevention and treatment of cancer
GB201809946D0 (en) Prevention and treatment of cancer